Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II placebo-controlled dose-ranging study of SMP-986 in overactive bladder syndrome
ISRCTN63089812Phase 2Completed
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2006
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of Afacifenacin in overactive bladder (OAB) (5 arms), sponsored by Sumitomo Pharma. Started Dec 2006; status: completed.
02
Drugs
Afacifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on ISRCTN63089812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN63089812.